文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

头盔无创通气与常规呼吸支持对COVID-19所致急性低氧性呼吸衰竭患者死亡率的影响:HELMET-COVID随机临床试验

Effect of Helmet Noninvasive Ventilation vs Usual Respiratory Support on Mortality Among Patients With Acute Hypoxemic Respiratory Failure Due to COVID-19: The HELMET-COVID Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01
一句话结论在COVID-19所致急性低氧性呼吸衰竭患者中,头盔无创通气与常规呼吸支持相比未显著降低28天死亡率(27.0% vs 26.1%,RR 1.04,P=0.85),但效应估计不精确,不能排除潜在临床重要获益或 harm。

这项多中心、实用、随机临床试验在沙特阿拉伯和科威特的8个中心进行,纳入320例疑似或确诊COVID-19所致急性低氧性呼吸衰竭成人患者,随机接受头盔无创通气(n=159)或常规呼吸支持(n=161,包括面罩无创通气、经鼻高流量氧疗和标准氧疗)。主要终点28天全因死亡率在头盔组为27.0%(43/159),常规组为26.1%(42/161),风险差1.0%(95%CI -8.7%至10.6%),相对风险1.04(95%CI 0.72-1.49),P=0.85。28天内气管插管率头盔组47.2%(75/159) vs 常规组50.3%(81/161),风险差-3.1%(95%CI -14.1%至7.8%),相对风险0.94(95%CI 0.75-1.17)。所有预设次要终点均无显著差异。作者认为头盔无创通气未显著降低28天死亡率,但解释受效应估计不精确限制,不能排除潜在临床重要获益或危害。

要点

  • 在COVID-19所致急性低氧性呼吸衰竭成人中,头盔无创通气 vs 常规呼吸支持28天死亡率27.0% vs 26.1%,RR 1.04(95%CI 0.72-1.49),P=0.85,未达统计学显著。
  • 28天气管插管率头盔组47.2%(75/159) vs 常规组50.3%(81/161),RR 0.94(95%CI 0.75-1.17),未达统计学显著。
  • 气压伤发生率头盔组18.9%(30/159) vs 常规组15.5%(25/161);皮肤压力性损伤头盔组3.1%(5/159) vs 常规组6.2%(10/161)。
  • 严重不良事件头盔组2例 vs 常规组1例;所有预设次要终点两组间均无显著差异。
  • 作者认为结果受效应估计不精确限制,不能排除潜在临床重要获益或危害。

适用人群与场景

  • 成人急性低氧性呼吸衰竭患者(n=320),病因疑似或确诊COVID-19,纳入本随机临床试验。

处置流程与药物剂量

  • 头盔无创通气组(n=159)接受头盔接口无创通气。
  • 常规呼吸支持组(n=161)接受面罩无创通气、经鼻高流量氧疗或标准氧疗。

研究设计与关键结果

  • 多中心、实用、随机临床试验,在沙特阿拉伯和科威特的8个中心进行,2021年2月8日至2021年11月16日纳入320例成人急性低氧性呼吸衰竭(疑似或确诊COVID-19)患者,随机分为头盔无创通气组(n=159)和常规呼吸支持组(n=161);主要终点最终随访日期为2021年12月14日。
  • 随机322例,320例纳入主要分析,均完成试验;中位年龄58岁,男性187例(58.4%)。
  • 28天全因死亡率:头盔无创通气组43/159(27.0%) vs 常规呼吸支持组42/161(26.1%),风险差1.0%(95%CI -8.7%至10.6%),相对风险1.04(95%CI 0.72-1.49),P=0.85。
  • 28天内气管插管:头盔组75/159(47.2%) vs 常规组81/161(50.3%),风险差-3.1%(95%CI -14.1%至7.8%),相对风险0.94(95%CI 0.75-1.17)。
  • 气压伤:头盔组30/159(18.9%) vs 常规组25/161(15.5%);皮肤压力性损伤:头盔组5/159(3.1%) vs 常规组10/161(6.2%);严重不良事件:头盔组2例 vs 常规组1例。
  • 所有预设次要终点两组间均无显著差异。

证据类型、等级与局限

  • 证据类型:多中心、实用、随机临床试验(HELMET-COVID)。
  • 局限:作者指出解释受效应估计不精确限制,不能排除潜在临床重要获益或危害。

对床旁实践的改变

  • 作者认为,在COVID-19所致急性低氧性呼吸衰竭患者中,头盔无创通气与常规呼吸支持相比未显著降低28天死亡率;解读受效应估计不精确限制,不能排除潜在临床重要获益或危害。

指南或共识出处

  • HELMET-COVID随机临床试验,ClinicalTrials.gov标识符NCT04477668。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Helmet noninvasive ventilation has been used in patients with COVID-19 with the premise that helmet interface is more effective than mask interface in delivering prolonged treatments with high positive airway pressure, but data about its effectiveness are limited.

OBJECTIVE: To evaluate whether helmet noninvasive ventilation compared with usual respiratory support reduces mortality in patients with acute hypoxemic respiratory failure due to COVID-19 pneumonia.

DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, pragmatic, randomized clinical trial that was conducted in 8 sites in Saudi Arabia and Kuwait between February 8, 2021, and November 16, 2021. Adult patients with acute hypoxemic respiratory failure (n = 320) due to suspected or confirmed COVID-19 were included. The final follow-up date for the primary outcome was December 14, 2021.

INTERVENTIONS: Patients were randomized to receive helmet noninvasive ventilation (n = 159) or usual respiratory support (n = 161), which included mask noninvasive ventilation, high-flow nasal oxygen, and standard oxygen.

MAIN OUTCOMES AND MEASURES: The primary outcome was 28-day all-cause mortality. There were 12 prespecified secondary outcomes, including endotracheal intubation, barotrauma, skin pressure injury, and serious adverse events.

RESULTS: Among 322 patients who were randomized, 320 were included in the primary analysis, all of whom completed the trial. Median age was 58 years, and 187 were men (58.4%). Within 28 days, 43 of 159 patients (27.0%) died in the helmet noninvasive ventilation group compared with 42 of 161 (26.1%) in the usual respiratory support group (risk difference, 1.0% [95% CI, -8.7% to 10.6%]; relative risk, 1.04 [95% CI, 0.72-1.49]; P = .85). Within 28 days, 75 of 159 patients (47.2%) required endotracheal intubation in the helmet noninvasive ventilation group compared with 81 of 161 (50.3%) in the usual respiratory support group (risk difference, -3.1% [95% CI, -14.1% to 7.8%]; relative risk, 0.94 [95% CI, 0.75-1.17]). There were no significant differences between the 2 groups in any of the prespecified secondary end points. Barotrauma occurred in 30 of 159 patients (18.9%) in the helmet noninvasive ventilation group and 25 of 161 (15.5%) in the usual respiratory support group. Skin pressure injury occurred in 5 of 159 patients (3.1%) in the helmet noninvasive ventilation group and 10 of 161 (6.2%) in the usual respiratory support group. There were 2 serious adverse events in the helmet noninvasive ventilation group and 1 in the usual respiratory support group.

CONCLUSIONS AND RELEVANCE: Results of this study suggest that helmet noninvasive ventilation did not significantly reduce 28-day mortality compared with usual respiratory support among patients with acute hypoxemic respiratory failure due to COVID-19 pneumonia. However, interpretation of the findings is limited by imprecision in the effect estimate, which does not exclude potentially clinically important benefit or harm.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04477668.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Arabi YM, Aldekhyl S, Al Qahtani S, et al. Effect of Helmet Noninvasive Ventilation vs Usual Respiratory Support on Mortality Among Patients With Acute Hypoxemic Respiratory Failure Due to COVID-19: The HELMET-COVID Randomized Clinical Trial. JAMA. 2022. PMID: 36125473. doi:10.1001/jama.2022.15599

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。